Investigational drug · Phase 2
Rimiducid
Also called: AP1903
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child.
Phase 2Last checked: Nov 20, 2026Latest source record: May 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
33
Any phase or sponsor naming "Rimiducid"
First trial start
2013
Mar 2013
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Rimiducid", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndromes
- Leukemia, Acute Myeloid (AML), Child
- Lymphoma, Non-Hodgkin
- Primary Immune Deficiency Disorder
- Osteopetrosis
- Cytopenia
- Hemoglobinopathy in Children
- Anemia, Aplastic
- B2 Thymoma
Approved drugs for the same conditions: Acute lymphoblastic leukemia · Lymphoma (non-Hodgkin) · Myelodysplastic syndromes · Anemia · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Rimiducid" as an intervention, largest first.
- P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple MyelomaActive, not recruiting
Poseida Therapeutics, Inc.Industry
NCT04960579 · 275 participants (planned) · Start May 5, 2022 · Primary completion Mar 2029
Drug: P-BCMA-ALLO1 CAR-T cells; Rimiducid and 1 more · For: Multiple Myeloma
Sites: Goodyear, Arizona; San Diego, California; San Francisco, California · 23 sites in all
Bellicum PharmaceuticalsIndustry
NCT04650451 · 220 participants (planned) · Start Dec 7, 2020 · Primary completion Dec 31, 2025
Drug: chimeric antigen receptor (CAR) T cell therapy · For: HER-2 Gene Amplification; HER2-positive Gastric Cancer; HER2-positive Breast Cancer and 2 more
Sites: Duarte, California; La Jolla, California; Atlanta, Georgia · 7 sites in all
- Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell TransplantTerminated
Bellicum PharmaceuticalsIndustry
NCT02065869 · 187 participants · Start Apr 2014 · Primary completion Jun 2020
Drug: BPX-501 T cells; Rimiducid · For: Acute Lymphoblastic Leukemia; Leukemia, Acute Myeloid (AML), Child; Lymphoma, Non-Hodgkin and 10 more
Sites: Roma, Italy; London, United Kingdom; Newcastle upon Tyne, United Kingdom · 4 sites in all
Bellicum PharmaceuticalsIndustry
NCT03733249 · 187 participants · Start Jan 2017 · Primary completion Jun 30, 2020
Drug: Rimiducid; rivogenlecleucel · For: Acute Lymphoblastic Leukemia; Leukemia, Acute Myeloid (AML), Child; Lymphoma, Non-Hodgkin and 9 more
Sites: Rome, Italy
- P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid TumorsActive, not recruiting
Poseida Therapeutics, Inc.Industry
NCT05239143 · 180 participants (planned) · Start Feb 15, 2022 · Primary completion Apr 2039
Drug: P-MUC1C-ALLO1 CAR-T cells; Rimiducid · For: Breast Cancer; Ovarian Cancer; Non Small Cell Lung Cancer and 6 more
Sites: Irvine, California; Los Angeles, California; San Diego, California · 14 sites in all
- Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell TransplantActive, not recruiting
Bellicum PharmaceuticalsIndustry
NCT03301168 · 120 participants (planned) · Start Apr 2014 · Primary completion May 11, 2021
Drug: BPX-501 T cells; Rimiducid · For: Acute Lymphoblastic Leukemia; Leukemia, Acute Myeloid (AML), Child; Lymphoma, Non-Hodgkin and 6 more
Sites: Los Angeles, California; Palo Alto, California; Washington D.C., District of Columbia · 10 sites in all
- P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell MalignanciesActive, not recruiting
Poseida Therapeutics, Inc.Industry
NCT06014762 · 120 participants (planned) · Start Apr 16, 2024 · Primary completion Mar 2029
Drug: P-CD19CD20-ALLO1; Rimiducid · For: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High-grade B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma (PMBCL) and 7 more
Sites: Loma Linda, California; Los Angeles, California; Orlando, Florida · 16 sites in all
Poseida Therapeutics, Inc.Industry
NCT03288493 · 105 participants · Start Sep 20, 2017 · Primary completion Apr 27, 2022
Drug: P-BCMA-101 CAR-T cells; Rimiducid · For: Multiple Myeloma
Sites: Gilbert, Arizona; Davis, California; San Diego, California · 16 sites in all
- Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin LymphomaPivotal-lookingNot yet recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07164469 · 100 participants (planned) · Start Dec 28, 2026 · Primary completion Sep 30, 2031
Drug: Fludarabine; Cyclophosphamide and 2 more · For: Large B-cell Lymphoma; Hodgkin Lymphoma
Sites: Houston, Texas
- Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101Active, not recruiting
Poseida Therapeutics, Inc.Industry
NCT03741127 · 100 participants (planned) · Start Oct 29, 2018 · Primary completion Aug 2032
Drug: Rimiducid may be administered as indicated · For: Multiple Myeloma
Sites: Davis, California; San Diego, California; San Francisco, California · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- An inducible signal 1 booster overcomes limited access to antigen for solid tumor cell therapy.
Radecki KC, Manry D, Kirsh C, et al. · Mol Ther Oncol 2026
- Using the iCasp9 suicide strategy to control the growth and function of genome-edited B cells with redirected antigen specificity.
Léonard J, Cahen M, Tanguy AL, et al. · Mol Ther Oncol 2025
- GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.
Locatelli F, Pagliara D, De Ioris MA, et al. · Nat Med 2025
- PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial.
Stein MN, Dumbrava EE, Teply BA, et al. · Nat Commun 2024
- Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting.
Ventin M, Cattaneo G, Arya S, et al. · Clin Cancer Res 2024
- GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.
Ciccone R, Quintarelli C, Camera A, et al. · Clin Cancer Res 2024
Also in development for Acute Lymphoblastic Leukemia
- MK-1045CN-201Phase 36 trials
Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular
- rivogenlecleucelBPX-501 T cells, BPX-501Phase 22 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.